Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The molecular mechanisms of the interrelationship between cholinergic neurotransmission, processing of amyloid precursor protein (APP) and β‐amyloid (Aβ) production in vivo are still less understood. To reveal any effect of cholinergic dysfunction on APP processing in vivo, 11‐month‐old transgenic Tg2576 mice with Aβ plaque pathology received intraperitoneal injections of scopolamine at a daily dosage of 2 mg/kg body weight for 14 days in order to suppress cortical cholinergic transmission by chronic inhibition of muscarinic acetylcholine receptors. Scopolamine treatment of transgenic Tg2576 mice resulted in increased levels of fibrillar Aβ(1–40) and Aβ(1–42), while the soluble, SDS‐extractable Aβ level remained unchanged as compared to vehicle‐injected Tg2576 mice. α‐Secretase activity determined in cortical tissue from scopolamine‐treated Tg2576 mice was lower by about 30% as compared to that assayed in control mice, while β‐secretase activity and BACE1 protein expression appeared unaffected by scopolamine treatment. The amount of sAPPα, the product secreted by α‐secretase‐mediated APP cleavage, and the unprocessed APP were assayed in the soluble and membrane fraction, respectively, of cortical tissue preparations from treated and control mice by Western blotting. Using the anti antibody 6E10 which specifically labels human sAPPα and full length APP in transgenic Tg2576, an enhanced APP level was detected in the membrane fraction from treated mice as compared to controls, while in the soluble fraction scopolamine treatment did not affect the protein level of sAPPα. These data indicate an accumulation of APP in cortical membrane fraction in scopolamine‐treated Tg2576 mice presumably due to the decreased level of α‐secretase‐mediated APP cleavage, and further suggest that chronic suppresion of cortical muscarinic cholinergic transmission may alter the balance between α‐ and β‐secretory APP processing by favouring the amyloidogenic route.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“Proteolytic processing of the human APP transgene is performed by using the murine ‘‘secretase machinery’’, and levels of b-amyloid peptides increase exponentially between 9 and 21 months of age (Apelt and Schliebs, 2001; Apelt et al., 2004; Kawarabayashi et al., 2001; Kalback et al., 2002).”
MethodNitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898 · cited 2×
“Muscarinic acetylcholine receptor (mAChR) stimulation performed in cell culture and in intact tissue slices convincingly demonstrated that APP processing is regulated by cholinergic neurotransmission (Nitsch et al., 1992).”
BackgroundReversible memory loss in a mouse transgenic model of Alzheimer’s disease
Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · cited 1×
“The transgenic Tg2576 mouse used in this study, overexpresses the Swedish mutation of human APP, and demonstrates cognitive defects (see, e.g. Kotilinek et al., 2002) and the beginning of plaque formation at ages ranging between 9 and 12 months (Apelt et al., 2004).”
MethodNitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5191 · Cited by 244 · cited 2×
“Secretion of sAPPa was enhanced by electrical stimulation of tissue slices from rat brain, which could be blocked by the sodium-channel antagonist tetrodotoxin (Nitsch et al., 1993).”
Background
Cited by
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Self-citationThe significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Self-citationMolecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
“Alpha-Secretase activity determined in cortical tissue from scopolamine-treated Tg2576 mice was lower by about 30% as compared to controls [58].”
BackgroundPiccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Metadata
- Authors
- Liskowsky, W., & Schliebs, R.
- Venue
- International Journal of Developmental Neuroscience
- Publisher
- Wiley
- Published
- 2006-01-19
- Volume
- 24
- Issue
- 2-3
- Pages
- 149-156
- ISSN
- 0736-5748 (ISSN-L)
- 1873-474X
- OpenAlex
- W2028535639
- Cited by
- 73
- References
- 5
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. https://app.cochat.ai/papers/10.1016/j.ijdevneu.2005.11.010
- The paper
- Liskowsky, W., & Schliebs, R. (2006). Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. International Journal of Developmental Neuroscience. https://doi.org/10.1016/j.ijdevneu.2005.11.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.